Ballew Advisors, Inc Aeterna Zentaris Inc. Transaction History

Ballew Advisors, Inc

  • $141 Million
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 12, 2019
SELL
$1.3 - $3.87 $3,900 - $11,610
-3,000 Closed
0 $0
Q3 2018

Oct 30, 2018
BUY
$1.6 - $2.03 $4,800 - $6,089
3,000 New
3,000 $4,000

About Aeterna Zentaris Inc.

AEZS Quotes by TradingView
  • Ticker AEZS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,855,880
  • Market Cap $19.4M
  • Description
  • Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...
More about AEZS
Track This Portfolio

Track Ballew Advisors, Inc Portfolio

Follow Ballew Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballew Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ballew Advisors, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email